Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.
IPO Year: 1999
Exchange: AMEX
Website: palatin.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $2.00 → $5.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)
SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
424B3 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
EFFECT - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
S-1/A - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
10-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
S-1 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
Obesity programs:Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideTopline results expected 1Q calendar year 2025General obesity, weight loss management, and rare neuroendocrine and genetic diseases, including hypothalamic obesityMultiple clinical trials targeted to commence 2H calendar year 2025 with long-acting MC4R peptide and/or MC4R oral small molecule compoundsDry eye disease and other ocular programs, ulcerative colitis, and diabetic nephropathy programs:Program specific licensing/collaboration and spinout discussions ongoing with multiple deals targeted for calendar year 2025CRANBURY, N.J., Jan. 28, 2025 /PRNewswire/ -- Palatin Tech
Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathyDemonstrated efficacy at 6 months71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr)71% of patients achieved improved or stabilized estimated glomerular filtration rate (eGFR)Bremelanotide therapy increased urinary VEGF levels in 37.5% of patients and reduced urinary synaptopodin losses in 36% of patientsCRANBURY, N.J., Dec. 19, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanoc
CRANBURY, N.J., Dec. 16, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant exercise inducement agreement (the "inducement agreement") with an institutional investor to exercise certain outstanding warrants that the Company issued in June 2024 and October 2023 totaling 3,907,679 shares of the Company's common stock for gross proceeds of approximately $3.4 million.
Oral PL8177 may provide a safe, effective, and tolerable treatment option for ulcerative colitis patients prior to immunosuppressive therapies and steroid treatments, which have significant safety and tolerability concernsPreclinical data demonstrated that oral PL8177 caused diseased colons to move towards a healthy state and to resolve damaging inflammationData expected 1Q calendar year 2025CRANBURY, N.J., Nov. 25, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the completion of enrollment in its Phase 2 Study of PL81
Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a
CRANBURY, N.J., Nov. 8, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q1
Oral PL7737 significantly decreased food intake and body weightOral small molecule melanocortin 4 agonist (MC4R) could address unmet needs and challenges of current obesity treatmentsMultiple clinical trials targeted in calendar year 2025 for the Company's obesity programsCRANBURY, N.J., Nov. 4, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced that preclinical data from the Company's melanocortin 4 receptor (MC4R) selective PL7737 obesity program will be highlighted in a poster presentation at ObesityWeek
Topline results expected in 1Q calendar year 2025Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weightData will inform and support the Company's obesity programs using novel, long-acting and highly selective MC4R peptide and small molecule compounds for treating general obesity, weight loss management, and rare/orphan MC4R pathway diseases, including hypothalamic obesityCRANBURY, N.J., Oct. 31, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced it has completed enrollment i
Data presented from clinical and preclinical studiesMelanocortin agonism reduces stress signaling and resolves inflammationPotential to treat inflammatory diseases without immunosuppressionCRANBURY, N.J., Oct. 24, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, presented a poster titled "Harnessing the Melanocortin System to Heal Inflammatory Diseases" at the 19th Annual Peptide Therapeutics Symposium held October 22-23, 2024 in person and virtually in La Jolla, California. Paul S. Kayne, Ph.D., lead author and Vice President Biologica
High selectivity for MC4R significantly reduces potential for skin pigmentationMC4R is a well-validated target for treating obesityClinical studies with highly selective MC4R agonists targeted to commence in calendar year 2025CRANBURY, N.J., Oct. 23, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, presented a poster titled "Structural Modification Allows the Removal of Melanocortin Receptor 1 Agonism From Melanocortin Receptor 4 Agonists," at the 19th Annual Peptide Therapeutics Symposium held October 22-23, 2024 in person and virtuall
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4/A - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a
CRANBURY, N.J., Nov. 8, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q1
Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)Patient Dosing Commenced 3Q Calendar Year 2024Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024Topline Results Expected 1Q Calendar Year 2025Dry Eye Disease (DED): PL9643MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical StudiesFDA Confirms Protocols and EndpointsPatient Enrollment Start Expected 1Q Calendar Year 2025Topline Results Anticipated 4Q Calendar Year 2025Potential Partner Collaboration and Funding Discussions OngoingMale Sexual Dysfunction: Bremelanotide Co-Formulated with a PDE5i for the Treatment of Erectile Dysfunction (ED) in Patients That Do Not Resp
Teleconference and Webcast to be held on October 1, 2024 CRANBURY, N.J., Sept. 26, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2024 operating results on Tuesday, October 1, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on October 1, 2024 at 11:00 AM Eastern Time. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for th
CRANBURY, N.J., May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q3 Fiscal Yea
On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025)Multiple Secondary Symptom Endpoints Met, Statistical Significance (P<0.025)On an Intent-to-Treat Analysis, Co-Primary Sign Endpoint and Secondary Sign Endpoints Not MetPL9643 Demonstrated Superiority Over Vehicle in Multiple Sign EndpointsExcellent Safety and Tolerability ProfileFuture Discussions Planned with FDA Regarding Regulatory Approval PathCompany to Host Conference Call at 8:30 a.m. ET TodayCRANBURY, N.J., Feb. 28, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of
CRANBURY, N.J., Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q2
Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder (HSDD) Vyleesi® has experienced 8 Consecutive Quarters of Double-Digit Prescription Growth Acquisition Adds Another Commercial Stage, Patent Protected Product to Cosette's Rapidly Expanding Women's Health Portfolio Cosette Pharmaceuticals, Inc. ("Cosette"), a US-based specialty pharmaceutical company with a focus on women's health and cardiovascular medicines, has completed the acquisition of Vyleesi® from Palatin Technologies, Inc. (NYSE:PTN), which includes 5 Orange Book listed patents with protection up to 2041. Palatin and Cosette will ens
Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients EnrolledTopline Data Expected Late 4Q Calendar Year 2023Interim Analysis of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye Excellent Patient Safety and Tolerability Product ProfilePhase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Interim Analysis Targeted for 1Q Calendar Year 2024Topline Results Currently Expected First Half Calendar Year 2024Vyleesi®Net Product Revenue Increased 47% Over the Prior QuarterPrescriptions Dispensed Increased 16% Over the Prior Quarter6 Consecutive Quarters of Double-Di
CRANBURY, N.J., Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 28, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audi